[Barriers for Implementation of PGx Testing in Psychiatric Hospitals in Germany: Results of the FACT-PGx Study].

IF 0.6 4区 医学 Q4 CLINICAL NEUROLOGY Fortschritte Der Neurologie Psychiatrie Pub Date : 2024-06-01 Epub Date: 2023-05-02 DOI:10.1055/a-2060-0694
Martina Hahn, Amelie Merle Frantz, Andreas Eckert, Andreas Reif
{"title":"[Barriers for Implementation of PGx Testing in Psychiatric Hospitals in Germany: Results of the FACT-PGx Study].","authors":"Martina Hahn, Amelie Merle Frantz, Andreas Eckert, Andreas Reif","doi":"10.1055/a-2060-0694","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The FACT-PGx study was conducted to analyze barriers to implementation of pharmacogenetic testing in psychiatric hospitals in Germany and to propose solutions for its faster and easier implementation in all hospitals.</p><p><strong>Methods: </strong>104 patients (50% female) were genotyped and participated in the study. 67 completed a survey. To analyze the correlation between continuous data (age) of the survey, the wilcoxon rank test and for categorial data (education level, history of treatment and episodes), t-test was used.</p><p><strong>Results: </strong>No patient declined to be genotyped. 99% believed that genotyping could help to shorten their hospital stay. Patients >40 years of age and with higher educational levels were willing to pay for the PGx (p=0.009). On average, patients were willing to pay 117.42€ +/-140.49€ and to wait 15.83+/- 8.92 days for the results. Processes differed significantly between routine laboratory screening and PGx testing which could be a barrier for implementation.</p><p><strong>Conclusion: </strong>Patients are not barriers to but enablers of an implementation of PGx. New process flows can be barriers, but can be overcome by optimization.</p>","PeriodicalId":12353,"journal":{"name":"Fortschritte Der Neurologie Psychiatrie","volume":" ","pages":"221-229"},"PeriodicalIF":0.6000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fortschritte Der Neurologie Psychiatrie","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2060-0694","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/5/2 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: The FACT-PGx study was conducted to analyze barriers to implementation of pharmacogenetic testing in psychiatric hospitals in Germany and to propose solutions for its faster and easier implementation in all hospitals.

Methods: 104 patients (50% female) were genotyped and participated in the study. 67 completed a survey. To analyze the correlation between continuous data (age) of the survey, the wilcoxon rank test and for categorial data (education level, history of treatment and episodes), t-test was used.

Results: No patient declined to be genotyped. 99% believed that genotyping could help to shorten their hospital stay. Patients >40 years of age and with higher educational levels were willing to pay for the PGx (p=0.009). On average, patients were willing to pay 117.42€ +/-140.49€ and to wait 15.83+/- 8.92 days for the results. Processes differed significantly between routine laboratory screening and PGx testing which could be a barrier for implementation.

Conclusion: Patients are not barriers to but enablers of an implementation of PGx. New process flows can be barriers, but can be overcome by optimization.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[德国精神病院实施 PGx 检测的障碍:FACT-PGx研究的结果]。
目的:FACT-PGx 研究旨在分析德国精神病院实施药物基因检测的障碍,并提出解决方案,以便在所有医院更快、更方便地实施药物基因检测:方法:104 名患者(50% 为女性)接受了基因分型并参与了研究。67 人完成了一项调查。为了分析调查中连续数据(年龄)之间的相关性,采用了威尔科克逊秩检验,而对于分类数据(教育程度、治疗史和发病情况),则采用了 t 检验:没有患者拒绝接受基因分型。99%的患者认为基因分型有助于缩短住院时间。年龄大于 40 岁、受教育程度较高的患者愿意支付 PGx 费用(p=0.009)。患者平均愿意支付 117.42 欧元 +/-140.49 欧元,并愿意等待 15.83+/- 8.92 天以获得结果。常规实验室筛查和 PGx 检测的流程有很大不同,这可能是实施过程中的一个障碍:结论:患者不是实施 PGx 的障碍,而是促进因素。新的流程可能会成为障碍,但可以通过优化来克服。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.10
自引率
16.70%
发文量
139
审稿时长
6-12 weeks
期刊介绍: Fundiertes Wissen für den Berufsalltag Relevante Originalarbeiten Informative Übersichten zu wichtigen Themen Fortbildungsteil mit Zertifizierung – 36 CME-Punkte pro Jahr Interessante Kasuistiken Referiert & kommentiert: Internationale Studien Aktuelles zu Begutachtung und Neurobiologie International gelistet und häufig zitiert
期刊最新文献
[Correction: The pioneers Schwerin and Brandenburg-Görden in the development of alcohol use disorder therapy in the GDR]. [Antipsychotic Treatment of Alcohol Withdrawal Syndrome with Focus on Delirium Tremens: a Systematic Review]. [Comparative Harm/Benefit Analysis of Various Psychotropic Substances from the Perspective of German Drug Users and Addiction Medicine Experts - A Contribution to Psychoeducation of Substance-Addicted Individuals and Restriction/Legalization Debates]. [Pacemaker, organ or walking stick? Pre-op association with and post-op subjective perception of a deep brain stimulation device]. [Emerging suicidal ideation in a bipolar patient after taking pregabalin: a case report].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1